Breaking News

BryoLogyx Acquires Rights to Neurotrope’s Bryostatin-1

Bryostatin-1 will be chemically synthesized by Albany Molecular Research Inc. (AMRI) in collaboration with BryoLogyx

By: Contract Pharma

Contract Pharma Staff

BryoLogyx Inc. has entered into two agreements with Neurotrope, Inc. to acquire Neurotrope’s preclinical data and drug product bryostatin-1 for an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for clinical trials and commercialization for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). F...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters